These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3493632)

  • 1. Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders.
    Klein P; Lees A; Stern G
    Adv Neurol; 1987; 45():603-4. PubMed ID: 3493632
    [No Abstract]   [Full Text] [Related]  

  • 2. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
    Trouillas P; Garde A; Robert JM; Renaud B; Adeleine P; Bard J; Brudon F
    Rev Neurol (Paris); 1982; 138(5):415-35. PubMed ID: 6983101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
    Trouillas P; Garde A; Robert JM; Adeleine P
    C R Seances Acad Sci III; 1981 Jan; 292(1):119-22. PubMed ID: 6786764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of 5 hydroxy-tryptophan in Parkinson's disease].
    Bastard J; Truelle JL; Emile J
    Nouv Presse Med; 1976 Sep; 5(29):1836-7. PubMed ID: 787922
    [No Abstract]   [Full Text] [Related]  

  • 5. [L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
    Sano I; Taniguchi K
    Munch Med Wochenschr; 1972 Oct; 114(40):1717-9. PubMed ID: 4538893
    [No Abstract]   [Full Text] [Related]  

  • 6. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
    Trouillas P
    Ital J Neurol Sci; 1984 Sep; 5(3):253-66. PubMed ID: 6334064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
    Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
    Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific influences of cerebellar dysfunctions on gait.
    Ilg W; Golla H; Thier P; Giese MA
    Brain; 2007 Mar; 130(Pt 3):786-98. PubMed ID: 17287287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postural control, gait, and dopamine functions in parkinsonian movement disorders.
    Bohnen NI; Cham R
    Clin Geriatr Med; 2006 Nov; 22(4):797-812, vi. PubMed ID: 17000336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of buspirone for the treatment of cerebellar ataxia in an older individual.
    Holroyd-Leduc JM; Liu BA; Maki BE; Zecevic A; Herrmann N; Black SE
    Can J Clin Pharmacol; 2005; 12(3):e218-21. PubMed ID: 16278493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gait and balance disorders in Parkinson's disease: impaired active braking of the fall of centre of gravity.
    Chastan N; Do MC; Bonneville F; Torny F; Bloch F; Westby GW; Dormont D; Agid Y; Welter ML
    Mov Disord; 2009 Jan; 24(2):188-95. PubMed ID: 18973252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pallidotomy on gait and balance.
    Jankovic J; Lai EC; Ondo WG; Roberts-Warrior D; Olson SL; Krauss JK; Grossman RG
    Adv Neurol; 2001; 87():271-81. PubMed ID: 11347232
    [No Abstract]   [Full Text] [Related]  

  • 13. ["Precursor-therapy" with active amines. 2. Treatment of Parkinson's disease by L-5-HTP (L-5-hydroxytryptophan)].
    Sano I; Taniguchi K
    Seishin Shinkeigaku Zasshi; 1971; 73(11):835-9. PubMed ID: 5316906
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved asymmetry of gait in Parkinson's disease with DBS: gait and postural instability in Parkinson's disease treated with bilateral deep brain stimulation in the subthalamic nucleus.
    Johnsen EL; Mogensen PH; Sunde NA; Østergaard K
    Mov Disord; 2009 Mar; 24(4):590-7. PubMed ID: 19097189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Other trials with drug therapy in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2115-7. PubMed ID: 4590072
    [No Abstract]   [Full Text] [Related]  

  • 16. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 17. [Gait and dementias].
    Manckoundia P; Mourey F; Pfitzenmeyer P
    Ann Readapt Med Phys; 2008 Nov; 51(8):692-700. PubMed ID: 18789549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oculomotor characteristics of parkinsonism in comparison with those of cerebellar ataxia.
    Shimizu N; Mizuno M
    J Neural Transm Suppl; 1983; 19():233-42. PubMed ID: 6583310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 20. Relative contributions of balance and voluntary leg-coordination deficits to cerebellar gait ataxia.
    Morton SM; Bastian AJ
    J Neurophysiol; 2003 Apr; 89(4):1844-56. PubMed ID: 12612041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.